<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881059</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-084</org_study_id>
    <secondary_id>2018-004293-10</secondary_id>
    <nct_id>NCT03881059</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Multiple Doses of BMS-986165 in Subjects With Active Psoriatic Arthritis (PsA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A&#xD;
      or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is intended to evaluate the safety and efficacy of BMS-986165 Dose A or B once&#xD;
      daily (QD) compared with placebo in adults with active PsA. The primary endpoint is american&#xD;
      college of rheumatology (ACR) 20 response at Week 16 (Part A).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">April 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Investigative site staff, the Sponsor, and Participant will remain blinded to treatment assignment with the exception of an unblinded pharmacist, an unblinded study drug administrator (Part B), and an unblinded site monitor.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A participant is considered an ACR 20 responder if the following three conditions are met:&#xD;
≥ 20% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 20% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 20% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing &quot;no difficulty&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A participant is considered an ACR 50 responder if the following three conditions are met:&#xD;
≥ 50% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 50% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 50% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A participant is considered an ACR 70 responder if the following three conditions are met:&#xD;
≥ 70% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 70% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 70% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 3.2 are considered to have achieved low disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 2.6 are considered to have achieved remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Dactylitis Count</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: [{(A/B) - 1}*100]*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Dactylitis Resolution</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity.&#xD;
The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score.&#xD;
Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Minimal Disease Activity (MDA) Response</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes:&#xD;
Tender joint count ≤ 1&#xD;
Swollen joint count ≤ 1&#xD;
Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3%&#xD;
Subject Global Assessment of pain ≤ 15&#xD;
Subject Global Assessment of disease activity ≤ 20&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5&#xD;
Tender entheseal points ≤ 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP).&#xD;
Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP).&#xD;
Final scores are interpreted as follows:&#xD;
≤4 = Remission (REM)&#xD;
&gt; 4 and ≤ 28 = moderate disease activity (MDA)&#xD;
&gt;28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>PsARC consists of 4 measurements:&#xD;
tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15.&#xD;
In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis:&#xD;
Fatigue (medical)&#xD;
Spinal pain&#xD;
Joint pain and swelling&#xD;
Areas of localized tenderness&#xD;
Morning stiffness duration&#xD;
Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score</measure>
    <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
    <description>The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains:&#xD;
Time management: difficulty with handling time and scheduling demands (5 items)&#xD;
Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items)&#xD;
Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items)&#xD;
Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 (&quot;no difficulty&quot;) to 3 (&quot;unable to do&quot;). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response</measure>
    <time_frame>16 weeks after first dose</time_frame>
    <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events</measure>
    <time_frame>From first dose to 16 weeks later (for participants continuing in the study) or from first dose up to 30 days following the last dose (up to approximately 19 weeks) for participants who discontinued treatment prior to week 16 after first dose</time_frame>
    <description>This outcome describes the number of participants who experienced different types of adverse events, including:&#xD;
Adverse Events (AEs)&#xD;
Serious Adverse Events (SAEs)&#xD;
Adverse Events Leading to Discontinuation&#xD;
Target Adverse Events of Interest (AEIs). AEIs are AEs pre-specified by the sponsor, including the following categories: certain skin-related AEs (limited to acnes (acne or dermatitis acneiform) or folliculitis), infection AEs (limited to herpes zoster, influenza, opportunistic infections, and tuberculosis), and malignancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Laboratory Tests Abnormalities</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
    <description>Laboratory tests abnormalities were analyzed in the following categories:&#xD;
Chemistry (hypoalbuminemia, alkaline phosphatase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hypocalcemia, hypercalcemia, cholesterol high, CPK increased, creatinine increased, hypoglycemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia, hypertriglyceridemia).&#xD;
Hematology (anemia, lymphocyte/neutrophil/platelet count decreased, white blood cell decreased).&#xD;
Tests results were reported by worst toxicity grade (0 to 4) based on the CTC version 5.0.&#xD;
Only laboratory abnormalities with a worst toxicity grade 3 or higher in any of the above-mentioned tests are reported here</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Results</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Electrocardiogram (ECG) Heart Rate</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Diastolic Blood Pressure</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Heart Rate</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Respiratory Rate</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Systolic Blood Pressure</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Temperature</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs - Weight</measure>
    <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Active Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BMS-986165 Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: BMS-986165 Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Ustekinumab + BMS-986165 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BMS-986165 Dose A + Ustekinumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: BMS-986165 Dose B + Ustekinumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>BMS-986165 Placebo</intervention_name>
    <description>Participants will receive BMS-986165 matching placebo QD</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_label>Part B: Ustekinumab + BMS-986165 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165 Dose A</intervention_name>
    <description>Participants will receive BMS-986165 Dose A QD.</description>
    <arm_group_label>Part A: BMS-986165 Dose A</arm_group_label>
    <arm_group_label>Part B: BMS-986165 Dose A + Ustekinumab Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165 Dose B</intervention_name>
    <description>Participants will receive BMS-986165 dose B QD.</description>
    <arm_group_label>Part A: BMS-986165 Dose B</arm_group_label>
    <arm_group_label>Part B: BMS-986165 Dose B + Ustekinumab Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ustekinumab</intervention_name>
    <description>Participants will receive ustekinumab SQ injection QD.</description>
    <arm_group_label>Part B: Ustekinumab + BMS-986165 Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ustekinumab Placebo</intervention_name>
    <description>Participants will receive ustekinumab SQ matching placebo QD</description>
    <arm_group_label>Part B: BMS-986165 Dose A + Ustekinumab Placebo</arm_group_label>
    <arm_group_label>Part B: BMS-986165 Dose B + Ustekinumab Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with PsA for at least 6 months before screening, and who meet the&#xD;
             Classification Criteria for Psoriatic Arthritis (CASPAR) at screening&#xD;
&#xD;
          -  Participants either (i) cannot have prior exposure to biologics (biologic-naïve) or&#xD;
             (ii) have failed or been intolerant to 1 tumor necrosis factor -inhibitor (TNFi)&#xD;
             (TNFi-experienced). Failure is defined as lack of response or loss of response with at&#xD;
             least 3 months of therapy with an approved dose of a TNFi, as judged by the&#xD;
             investigator. Failure must have occurred at least 2 months prior to Day 1&#xD;
&#xD;
          -  Participants have at least 1 confirmed greater than or equal to (&gt;=) 2 centimeter (cm)&#xD;
             lesion of plaque psoriasis at screening&#xD;
&#xD;
          -  Participants have active arthritis as shown by a minimum of &gt;= 3 swollen joints and &gt;=&#xD;
             3 tender joints (66/68 joint counts) at screening and Day 1&#xD;
&#xD;
          -  High sensitivity C-reactive protein (hsCRP) &gt;= 3milligram per liter (mg/L) at&#xD;
             screening&#xD;
&#xD;
          -  Women of Childbearing Potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test within 24 hours prior to the start of study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has non-plaque psoriasis (that is (i.e.), guttate, inverse, pustular, erythrodermic or&#xD;
             drug-induced psoriasis) at screening or Day 1&#xD;
&#xD;
          -  Has any other autoimmune condition such as rheumatoid arthritis, etc. There are&#xD;
             exceptions for inflammatory bowel disease or uveitis as follows: currently active&#xD;
             disease is excluded but, a history of no longer active disease for at least 12 months&#xD;
             (including not being on medication) is allowed&#xD;
&#xD;
          -  Has active (i.e. currently symptomatic) fibromyalgia&#xD;
&#xD;
          -  History or evidence of active infection and/or febrile illness within 7 days prior to&#xD;
             Day 1 (example, bronchopulmonary, urinary, gastrointestinal, etc.)&#xD;
&#xD;
          -  History of recent serious bacterial, fungal, or viral infections requiring&#xD;
             hospitalization and intravenous (IV) antimicrobial treatment within 90 days prior to&#xD;
             screening, or any infection requiring antimicrobial treatment within 15 days prior to&#xD;
             Day 1&#xD;
&#xD;
          -  History of active tuberculosis (TB) prior to screening visit, regardless of completion&#xD;
             of adequate treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research - Covina Office</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego Medical Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants - Metrowest</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology &amp; Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BayCare Medical Group</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates - East Wichita</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Coast Rheumatology</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology-Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Muscle Medical Care and Research Institute - Lilington Office</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Salisbury</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research and Consulting</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Rheumatology</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Ramesh C. Gupta, MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <zip>77429-5890</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Rheumatology Associates</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L.K.N. Arthrocentrum, s.r.o</name>
      <address>
        <city>Hlu?</city>
        <zip>748 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Ostrava</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova s.r.o.</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthrocentrum</name>
      <address>
        <city>Praha 10</city>
        <zip>101 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affidea Praha</name>
      <address>
        <city>Praha 11 Chodov</city>
        <zip>148 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuselska Poliklinika</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky Ustav</name>
      <address>
        <city>Praha</city>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV-Medical Services, s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis PD Dr. med. Brandt Jurgens</name>
      <address>
        <city>Berlin</city>
        <zip>12161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRF II - Hamburger Rheuma Forschungszentrum II - MVZ fur Rheumatologie und Autoimmunmedizin Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO.MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinexpert Gyogycentrum</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magyar Honvedseg Egeszsegugyi Kozpont</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRU Hungary Egeszsegugyi es Szolgaltato Korlatolt Felelossegu Tarsasag</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aranyklinika</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMed Rehabilitacios es Diagnosztikai Kozpont</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Dr. Bugyi Istvan Korhaz</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Integrata di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteo-Medic</name>
      <address>
        <city>Bia?ystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Internistyczno-Reumatologiczny Piotr Adrian Klimiuk</name>
      <address>
        <city>Bialystok</city>
        <zip>15-077</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinicMed Daniluk Nowak Spolka Jawna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Osrodek Badan Klinicznych - Bydgoszcz</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-068</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Number 2 im. dr. Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Lek. Med. Barbara Bazela</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Badania Kliniczne</name>
      <address>
        <city>Krakow</city>
        <zip>30-002</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grazyna Pulka Specjalistyczny Osrodek All-med</name>
      <address>
        <city>Krak</city>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow</name>
      <address>
        <city>Krak</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMED Centrum Medyczne</name>
      <address>
        <city>Lodz</city>
        <zip>91-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej Lecznica Mak-Med Spolka Cywilna</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych S.C.</name>
      <address>
        <city>Poznan</city>
        <zip>60-773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ai Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Torun</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Medicus Zaklad Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-118</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ars Rheumatica - Reumatika Centrum Reumatologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED Warszawa Targowek</name>
      <address>
        <city>Warszawa</city>
        <zip>03-291</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WroMedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Oporow</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific Research Medical Complex</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Revma-Med</name>
      <address>
        <city>Kemerovo</city>
        <zip>650070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic on Maroseyka</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Health Family</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of the Republic of Karelia-Republican Hospital im.V.A.Baranova</name>
      <address>
        <city>Petrozavodsk</city>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic of Private Security Personnel</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Rheumatological Hospital Number 25</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Medical Consultation and Research Center-Practice</name>
      <address>
        <city>Yarolavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital named after NA Semashko</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Senora de la Esperanza</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Bradford</city>
        <zip>BD5 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Princess Alexandra Hospital NHS Trust</name>
      <address>
        <city>Harlow</city>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <results_first_submitted>April 23, 2021</results_first_submitted>
  <results_first_submitted_qc>April 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2021</results_first_posted>
  <last_update_submitted>April 23, 2021</last_update_submitted>
  <last_update_submitted_qc>April 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 23, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03881059/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03881059/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>203 participants were randomized and treated.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matching BMS-986165</description>
        </group>
        <group group_id="P2">
          <title>BMS-986165 6 mg</title>
          <description>BMS-986165 6 mg administered QD for 16 weeks</description>
        </group>
        <group group_id="P3">
          <title>BMS-986165 12 mg</title>
          <description>BMS-986165 12 mg administered QD for 16 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized by mistake with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matching BMS-986165</description>
        </group>
        <group group_id="B2">
          <title>BMS-986165 6 mg</title>
          <description>BMS-986165 6 mg administered QD for 16 weeks</description>
        </group>
        <group group_id="B3">
          <title>BMS-986165 12 mg</title>
          <description>BMS-986165 12 mg administered QD for 16 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="203"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="13.17"/>
                    <measurement group_id="B2" value="50.5" spread="13.69"/>
                    <measurement group_id="B3" value="50.5" spread="13.75"/>
                    <measurement group_id="B4" value="49.8" spread="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16</title>
        <description>A participant is considered an ACR 20 responder if the following three conditions are met:&#xD;
≥ 20% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 20% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 20% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 20 Response at Week 16</title>
          <description>A participant is considered an ACR 20 responder if the following three conditions are met:&#xD;
≥ 20% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 20% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 20% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" lower_limit="20.6" upper_limit="43.1"/>
                    <measurement group_id="O2" value="52.9" lower_limit="41.2" upper_limit="64.6"/>
                    <measurement group_id="O3" value="62.7" lower_limit="51.1" upper_limit="74.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Slope Coefficient of Dose</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.05</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing &quot;no difficulty&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 to 3, with 0 representing &quot;no difficulty&quot; and 3 as &quot;unable to do&quot;. Any activity that requires assistance from another individual or an assistive device adjusts to a minimum score of 2. For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.066"/>
                    <measurement group_id="O2" value="-0.37" spread="0.065"/>
                    <measurement group_id="O3" value="-0.39" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response</title>
        <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with at least 3% Body Surface Area (BSA) involvement at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 75 Response</title>
          <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 75 response rate represents the percentage of participants who experienced at least a 75% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
          <population>All treated participants with at least 3% Body Surface Area (BSA) involvement at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4" lower_limit="9.6" upper_limit="31.1"/>
                    <measurement group_id="O2" value="42.4" lower_limit="29.8" upper_limit="55.0"/>
                    <measurement group_id="O3" value="59.6" lower_limit="46.3" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</title>
        <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Physical Component Summary (PCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</title>
          <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.97"/>
                    <measurement group_id="O2" value="5.6" spread="0.94"/>
                    <measurement group_id="O3" value="5.8" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16</title>
        <description>A participant is considered an ACR 50 responder if the following three conditions are met:&#xD;
≥ 50% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 50% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 50% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 50 Response at Week 16</title>
          <description>A participant is considered an ACR 50 responder if the following three conditions are met:&#xD;
≥ 50% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 50% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 50% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6" lower_limit="3.2" upper_limit="18.0"/>
                    <measurement group_id="O2" value="24.3" lower_limit="14.2" upper_limit="34.3"/>
                    <measurement group_id="O3" value="32.8" lower_limit="21.6" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16</title>
        <description>A participant is considered an ACR 70 responder if the following three conditions are met:&#xD;
≥ 70% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 70% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 70% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the American College of Rheumatology (ACR) 70 Response at Week 16</title>
          <description>A participant is considered an ACR 70 responder if the following three conditions are met:&#xD;
≥ 70% improvement from baseline in the number of tender joints (68 joint count).&#xD;
≥ 70% improvement from baseline in the number of swollen joints (66 joint count).&#xD;
≥ 70% improvement from baseline in at least 3 of the following 5 domains:&#xD;
Subject Global Assessment of disease activity&#xD;
Physician Global Assessment of psoriatic arthritis&#xD;
Subject Global Assessment of pain&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI)&#xD;
High-sensitivity C-reactive protein (hsCRP)</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.0" upper_limit="4.5"/>
                    <measurement group_id="O2" value="14.3" lower_limit="6.1" upper_limit="22.5"/>
                    <measurement group_id="O3" value="19.4" lower_limit="9.9" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</title>
        <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 3.2 are considered to have achieved low disease activity.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Low Disease Activity According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</title>
          <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 3.2 are considered to have achieved low disease activity.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" lower_limit="12.6" upper_limit="32.8"/>
                    <measurement group_id="O2" value="37.1" lower_limit="25.8" upper_limit="48.5"/>
                    <measurement group_id="O3" value="43.3" lower_limit="31.4" upper_limit="55.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</title>
        <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 2.6 are considered to have achieved remission.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Remission According to the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP)</title>
          <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Only participants with a score &lt; 2.6 are considered to have achieved remission.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="0.3" upper_limit="11.8"/>
                    <measurement group_id="O2" value="24.3" lower_limit="14.2" upper_limit="34.3"/>
                    <measurement group_id="O3" value="25.4" lower_limit="15.0" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score</title>
        <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Disease Activity Score-28 Using C Reactive Protein (DAS 28 CRP) Score</title>
          <description>A Disease Activity Score (DAS) is a scoring system used to assess disease activity.&#xD;
DAS 28 CRP is a composite outcome measure that assesses:&#xD;
How many joints in the hands (including metacarpophalangeal and proximal interphalangeal joints, but excluding distal interphalangeal joints), wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28.&#xD;
C Reactive Protein (CRP) levels in the blood (as a measure of the degree of inflammation)&#xD;
Subject Global Assessment of disease activity&#xD;
The results are combined to produce the DAS 28 CRP score, which correlates with the extent of disease activity as follows:&#xD;
&lt; 2.6: Disease remission&#xD;
2.6 - 3.2: Low disease activity&#xD;
3.2 - 5.1: Moderate disease activity&#xD;
&gt; 5.1: High disease activity. Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="0.15"/>
                    <measurement group_id="O2" value="-1.7" spread="0.15"/>
                    <measurement group_id="O3" value="-1.7" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Dactylitis Count</title>
        <description>The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with dactylitis count ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Dactylitis Count</title>
          <description>The number of digits in hands and feet with dactylitis (Tender + Non-Tender) was counted and change from baseline at week 16 was assessed.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with dactylitis count ≥ 1 at baseline</population>
          <units>Digits with dactylitis</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.40"/>
                    <measurement group_id="O2" value="-2.0" spread="0.38"/>
                    <measurement group_id="O3" value="-2.5" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score</title>
        <description>The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: [{(A/B) - 1}*100]*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with LDI score &gt; 0 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Leeds Dactylitis Index (LDI) Basic Score</title>
          <description>The Leeds Dactylitis Index (LDI) Basic is a quantitative measurement of dactylitis in the 20 digits using a dactylometer. The circumference of the affected and contralateral digits, and tenderness of the affected digits are measured to generate a total score. For each dactylitic digit, the final score is defined as: [{(A/B) - 1}*100]*C, where A is circumference of involved digit, B is circumference of the opposite, unaffected, digit or reference, and C is tenderness (0 or 1). The total score is determined by summing the relative score of all digits. A higher score indicates worse dactylitis.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with LDI score &gt; 0 at baseline</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.3" spread="8.87"/>
                    <measurement group_id="O2" value="-41.8" spread="8.35"/>
                    <measurement group_id="O3" value="-44.5" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Dactylitis Resolution</title>
        <description>Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with dactylitis count (tender digits only) ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Dactylitis Resolution</title>
          <description>Dactylitis resolution (tender digits only) is defined as a dactylitis count of 0 in participants with dactylitis count ≥ 1 at baseline</description>
          <population>All treated participants with dactylitis count (tender digits only) ≥ 1 at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="40.8" upper_limit="79.2"/>
                    <measurement group_id="O2" value="76.7" lower_limit="61.5" upper_limit="91.8"/>
                    <measurement group_id="O3" value="79.2" lower_limit="62.9" upper_limit="95.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)</title>
        <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with LEI score ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Enthesitis by the Leeds Enthesitis Index (LEI)</title>
          <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with LEI score ≥ 1 at baseline</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.27"/>
                    <measurement group_id="O2" value="-1.5" spread="0.25"/>
                    <measurement group_id="O3" value="-1.7" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</title>
        <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with SPARCC enthesitis index score ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in Enthesitis by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</title>
          <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with SPARCC enthesitis index score ≥ 1 at baseline</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.54"/>
                    <measurement group_id="O2" value="-2.9" spread="0.48"/>
                    <measurement group_id="O3" value="-3.1" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)</title>
        <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with LEI score ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Enthesitis Resolution by the Leeds Enthesitis Index (LEI)</title>
          <description>The LEI was developed specifically for psoriatic arthritis. An overall score of 0 to 6 is derived from the presence or absence of tenderness at 6 entheseal sites (right and left: lateral epicondyle, medial femoral condyle, and Achilles tendon insertion) at the time of evaluation. A higher count indicates a greater enthesitis burden.&#xD;
Enthesitis resolution is defined as s LEI score of 0, in subjects with LEI ≥ 1 at baseline</description>
          <population>All treated participants with LEI score ≥ 1 at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" lower_limit="7.9" upper_limit="37.3"/>
                    <measurement group_id="O2" value="51.3" lower_limit="35.6" upper_limit="67.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="30.8" upper_limit="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</title>
        <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with SPARCC enthesitis index score ≥ 1 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Enthesitis Resolution by the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index</title>
          <description>The SPARCC Enthesitis Index has a 0 to 16 score that is derived from the evaluation of 8 locations: the greater trochanter (R/L), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial and lateral epicondyles (R/L), and the supraspinatus insertion (R/L). A higher count indicates a higher enthesitis burden based on the current evaluation.&#xD;
Enthesitis resolution defined as a SPARCC enthesitis index score of 0, in subjects with SPARCC ≥ 1 at baseline.</description>
          <population>All treated participants with SPARCC enthesitis index score ≥ 1 at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="4.8" upper_limit="30.5"/>
                    <measurement group_id="O2" value="51.2" lower_limit="36.2" upper_limit="66.1"/>
                    <measurement group_id="O3" value="41.2" lower_limit="24.6" upper_limit="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1</title>
        <description>In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity.&#xD;
The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score.&#xD;
Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with PGA-F score ≥ 3 at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Physicians Global Assessment-Fingernails (PGA-F) Score of 0 or 1</title>
          <description>In participants with psoriasis fingernail involvement, the PGA-F score is used to evaluate the overall condition of the fingernails in terms of disease severity.&#xD;
The assessment is performed by the investigator, who rates the fingernail condition on a 5-point scale based on the higher of the nail bed/nail matrix score.&#xD;
Scores are 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe).</description>
          <population>All treated participants with PGA-F score ≥ 3 at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="21.4" lower_limit="0.0" upper_limit="42.9"/>
                    <measurement group_id="O3" value="50.0" lower_limit="28.1" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Minimal Disease Activity (MDA) Response</title>
        <description>A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes:&#xD;
Tender joint count ≤ 1&#xD;
Swollen joint count ≤ 1&#xD;
Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3%&#xD;
Subject Global Assessment of pain ≤ 15&#xD;
Subject Global Assessment of disease activity ≤ 20&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5&#xD;
Tender entheseal points ≤ 1</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Minimal Disease Activity (MDA) Response</title>
          <description>A Minimal Disease Activity (MDA) responder is defined as a participant fulfilling 5 of the following 7 outcomes:&#xD;
Tender joint count ≤ 1&#xD;
Swollen joint count ≤ 1&#xD;
Psoriasis Area and Severity Index (PASI) ≤ 1 or body surface area (BSA) ≤ 3%&#xD;
Subject Global Assessment of pain ≤ 15&#xD;
Subject Global Assessment of disease activity ≤ 20&#xD;
Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5&#xD;
Tender entheseal points ≤ 1</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="1.2" upper_limit="14.0"/>
                    <measurement group_id="O2" value="22.9" lower_limit="13.0" upper_limit="32.7"/>
                    <measurement group_id="O3" value="23.9" lower_limit="13.7" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)</title>
        <description>PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP).&#xD;
Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Psoriatic Arthritis Disease Activity Score (PASDAS)</title>
          <description>PASDAS is a composite measure calculated from the Physician Global Assessment of psoriatic arthritis, the Subject Global Assessment of disease activity, the Short Form Health Survey-36 Item (SF-36) Physical Component Summary (PCS), the swollen joint count, the tender joint count, the Leeds Enthesitis Index (LEI), the Leeds Dactylitis Index (LDI) (Basic), and the the levels of high-sensitivity C-reactive Protein (hsCRP).&#xD;
Each item contributes differently to the final score, which ranges from 0 to 10 (higher scores represent a higher level of disease activity).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with available measurements</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.21"/>
                    <measurement group_id="O2" value="-2.0" spread="0.20"/>
                    <measurement group_id="O3" value="-2.1" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)</title>
        <description>DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP).&#xD;
Final scores are interpreted as follows:&#xD;
≤4 = Remission (REM)&#xD;
&gt; 4 and ≤ 28 = moderate disease activity (MDA)&#xD;
&gt;28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Disease Activity Index for Psoriatic Arthritis Score (DAPSA)</title>
          <description>DAPSA is a composite measure to assess peripheral joint involvement that is based upon numerical summation of 5 variables of disease activity: tender/painful joint count 68, swollen joint count 66, Subject Global Assessment of disease activity, Subject Global Assessment of pain, and the levels of C-reactive Protein (CRP).&#xD;
Final scores are interpreted as follows:&#xD;
≤4 = Remission (REM)&#xD;
&gt; 4 and ≤ 28 = moderate disease activity (MDA)&#xD;
&gt;28 = high disease activity (HDA). Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.3" spread="2.20"/>
                    <measurement group_id="O2" value="-23.2" spread="2.16"/>
                    <measurement group_id="O3" value="-25.6" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)</title>
        <description>PsARC consists of 4 measurements:&#xD;
tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15.&#xD;
In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)</title>
          <description>PsARC consists of 4 measurements:&#xD;
tender/painful joint count, swollen joint count, Physician Global Assessment of psoriatic arthritis, and Subject Global Assessment of pain ≤ 15.&#xD;
In order to be classified as a PsARC responder, participants must achieve improvement in 2 of 4 measures, one of which must be joint pain or swelling, without worsening in any measure.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="42.5" upper_limit="66.6"/>
                    <measurement group_id="O2" value="75.7" lower_limit="65.7" upper_limit="85.8"/>
                    <measurement group_id="O3" value="74.6" lower_limit="64.2" upper_limit="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
        <description>In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis:&#xD;
Fatigue (medical)&#xD;
Spinal pain&#xD;
Joint pain and swelling&#xD;
Areas of localized tenderness&#xD;
Morning stiffness duration&#xD;
Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with evidence of psoriatic arthritis spondylitis at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)</title>
          <description>In participants with baseline evidence of Psoriatic Arthritis Spondylitis, symptoms are evaluated using the BASDAI, which consists of a 0 to 100 scale measuring discomfort, pain, and fatigue in response to 6 questions pertaining to the 5 major symptoms of ankylosing spondylitis:&#xD;
Fatigue (medical)&#xD;
Spinal pain&#xD;
Joint pain and swelling&#xD;
Areas of localized tenderness&#xD;
Morning stiffness duration&#xD;
Morning stiffness severity A higher count indicates worse disease. Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with evidence of psoriatic arthritis spondylitis at baseline</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="0.55"/>
                    <measurement group_id="O2" value="-2.0" spread="0.48"/>
                    <measurement group_id="O3" value="-2.2" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</title>
        <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Mental Component Summary (MCS) Score of the Short Form Health Survey-36 (SF-36) Questionnaire</title>
          <description>The SF-36 is a patient-reported outcome measure, which includes 36 items in a Likert-type format to measure the following 8 health dimensions over the past week: 1) limitations in physical activities, such as bathing or dressing 2) limitations in social activities because of physical or emotional problems 3) limitations in usual role activities because of physical health problems 4) bodily pain 5) general mental health (psychological distress and well-being) 6) limitations in usual role activities because of emotional problems 7) vitality (energy and fatigue) and 8) general health perceptions.&#xD;
The 8 health dimensions assessed are grouped into 2 main components, physical and mental. Each of the 8 dimensions contribute to both the Physical Component Summary (PCS) score and the Mental Component Summary (MCS) score.&#xD;
PCS and MCS scores range from 0 to 100, with high scores indicating a better health status.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.00"/>
                    <measurement group_id="O2" value="3.6" spread="0.97"/>
                    <measurement group_id="O3" value="3.5" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score</title>
        <description>PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Psoriatic Arthritis Impact of Disease (PsAID) 12 Score</title>
          <description>PsAID is a 12-item self-report that measures psoriatic arthritis symptoms and impact of disease. Each item is scored on a 0 to 10 numeric rating scale, and each item contributes differently to the final score. Weighted scores for each item are summed and divided by 20 to generate the final score, ranging from 0 to 10 (higher values indicate worse health).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.26"/>
                    <measurement group_id="O2" value="-2.1" spread="0.26"/>
                    <measurement group_id="O3" value="-2.3" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score</title>
        <description>The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score</title>
          <description>The FACIT-Fatigue instrument is a questionnaire used to evaluate a range of self-reported symptoms over the past week, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The questionnaire is composed of 13 questions (Short Form 13a) and each question is scored from 1 to 5. The final score results from the sum of the scores of the 13 questions, and ranges from 13 (most desirable outcome) to 65 (least desirable outcome).&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants with available measurements</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.17"/>
                    <measurement group_id="O2" value="5.6" spread="1.16"/>
                    <measurement group_id="O3" value="7.2" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score</title>
        <description>The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains:&#xD;
Time management: difficulty with handling time and scheduling demands (5 items)&#xD;
Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items)&#xD;
Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items)&#xD;
Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
        <time_frame>From baseline (day of the first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Change From Baseline in the Work Limitation Questionnaire (WLQ) Score</title>
          <description>The Work Limitation Questionnaire (WLQ) is a 25-item self-report that measures the on-the-job impact of chronic health conditions and treatment over the past 2 weeks. It focuses on assessing limitations while performing specific job demands from the following 4 domains:&#xD;
Time management: difficulty with handling time and scheduling demands (5 items)&#xD;
Physical demands: ability to perform job tasks that involve bodily strength, movement, endurance, coordination, and flexibility (6 items)&#xD;
Mental-interpersonal demands: cognitively demanding tasks and on-the-job social interactions (9 items)&#xD;
Output demands: concerns reduced work productivity (5 items). Final score ranges from 0 (limited none of the time) to 100 (limited all of the time). The score can be used to calculate a percent of lost work productivity due to a particular disease state.&#xD;
Adjusted change represents a change from baseline based on statistical model.</description>
          <population>All treated participants</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="0.69"/>
                    <measurement group_id="O2" value="-1.9" spread="0.67"/>
                    <measurement group_id="O3" value="-2.7" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response</title>
        <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 (&quot;no difficulty&quot;) to 3 (&quot;unable to do&quot;). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Health Assessment Questionnaire-Disability Index (HAQ-DI) 0.35 Response</title>
          <description>The HAQ-DI is measured by the use of a patient-reported outcome measure questionnaire, assessing the degree of difficulty a person has experienced during the past week in 8 domains of daily living activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities. Each activity category consists of 2 to 3 questions (total of 20 questions). For reach question the level of activity is scored from 0 (&quot;no difficulty&quot;) to 3 (&quot;unable to do&quot;). For each activity category, the highest score reported in the 2 or 3 questions pertinent to that category represents the category score. Scores from the 8 categories are then summed and divided by 8 to generate the final score. The final score can range from 0 (most desirable outcome) to 3 (least desirable outcome).&#xD;
A HAQ-DI 0.35 responder is defined as a participant with an improvement from baseline in HAQ-DI score of at least 0.35.</description>
          <population>All treated participants</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" lower_limit="6.5" upper_limit="23.8"/>
                    <measurement group_id="O2" value="38.6" lower_limit="27.2" upper_limit="50.0"/>
                    <measurement group_id="O3" value="40.3" lower_limit="28.6" upper_limit="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response</title>
        <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
        <time_frame>16 weeks after first dose</time_frame>
        <population>All treated participants with at least 3% Body Surface Area (BSA) involvement at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving the Psoriasis Area and Severity Index (PASI) 90 Response</title>
          <description>The PASI is a measure of the average erythema, induration thickness and scaling of psoriatic skin lesions (each graded on a 0 to 4 scale), weighted by the area of involvement (head, arms, trunk to groin, and legs to top of buttocks). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. The PASI 90 response rate represents the percentage of participants who experienced at least a 90% improvement in PASI score as compared with the baseline value. PASI assessment was performed by trained professionals.</description>
          <population>All treated participants with at least 3% Body Surface Area (BSA) involvement at baseline</population>
          <units>Percent of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="1.5" upper_limit="17.0"/>
                    <measurement group_id="O2" value="20.3" lower_limit="10.1" upper_limit="30.6"/>
                    <measurement group_id="O3" value="34.6" lower_limit="21.7" upper_limit="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events</title>
        <description>This outcome describes the number of participants who experienced different types of adverse events, including:&#xD;
Adverse Events (AEs)&#xD;
Serious Adverse Events (SAEs)&#xD;
Adverse Events Leading to Discontinuation&#xD;
Target Adverse Events of Interest (AEIs). AEIs are AEs pre-specified by the sponsor, including the following categories: certain skin-related AEs (limited to acnes (acne or dermatitis acneiform) or folliculitis), infection AEs (limited to herpes zoster, influenza, opportunistic infections, and tuberculosis), and malignancy</description>
        <time_frame>From first dose to 16 weeks later (for participants continuing in the study) or from first dose up to 30 days following the last dose (up to approximately 19 weeks) for participants who discontinued treatment prior to week 16 after first dose</time_frame>
        <population>All treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events</title>
          <description>This outcome describes the number of participants who experienced different types of adverse events, including:&#xD;
Adverse Events (AEs)&#xD;
Serious Adverse Events (SAEs)&#xD;
Adverse Events Leading to Discontinuation&#xD;
Target Adverse Events of Interest (AEIs). AEIs are AEs pre-specified by the sponsor, including the following categories: certain skin-related AEs (limited to acnes (acne or dermatitis acneiform) or folliculitis), infection AEs (limited to herpes zoster, influenza, opportunistic infections, and tuberculosis), and malignancy</description>
          <population>All treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEIs - Skin-related (acnes or folliculitis)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEIs - Pre-specified Infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEIs - malignancy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Laboratory Tests Abnormalities</title>
        <description>Laboratory tests abnormalities were analyzed in the following categories:&#xD;
Chemistry (hypoalbuminemia, alkaline phosphatase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hypocalcemia, hypercalcemia, cholesterol high, CPK increased, creatinine increased, hypoglycemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia, hypertriglyceridemia).&#xD;
Hematology (anemia, lymphocyte/neutrophil/platelet count decreased, white blood cell decreased).&#xD;
Tests results were reported by worst toxicity grade (0 to 4) based on the CTC version 5.0.&#xD;
Only laboratory abnormalities with a worst toxicity grade 3 or higher in any of the above-mentioned tests are reported here</description>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Laboratory Tests Abnormalities</title>
          <description>Laboratory tests abnormalities were analyzed in the following categories:&#xD;
Chemistry (hypoalbuminemia, alkaline phosphatase increased, alanine aminotransferase increased, aspartate aminotransferase increased, hypocalcemia, hypercalcemia, cholesterol high, CPK increased, creatinine increased, hypoglycemia, hypokalemia, hyperkalemia, hyponatremia, hypernatremia, hypertriglyceridemia).&#xD;
Hematology (anemia, lymphocyte/neutrophil/platelet count decreased, white blood cell decreased).&#xD;
Tests results were reported by worst toxicity grade (0 to 4) based on the CTC version 5.0.&#xD;
Only laboratory abnormalities with a worst toxicity grade 3 or higher in any of the above-mentioned tests are reported here</description>
          <population>All treated participants with available measurements</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Aspartate aminotransferase increased</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine phosphokinase (CPK)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertriglyceridemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anemia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte count decreased</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Results</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Results</title>
          <population>All treated participants with available measurements</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR Interval, Aggregate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="16.40"/>
                    <measurement group_id="O2" value="3.2" spread="17.83"/>
                    <measurement group_id="O3" value="-2.9" spread="37.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS Duration, Aggregate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="9.07"/>
                    <measurement group_id="O2" value="3.9" spread="11.58"/>
                    <measurement group_id="O3" value="-1.1" spread="13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval, Aggregate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="27.47"/>
                    <measurement group_id="O2" value="2.7" spread="28.56"/>
                    <measurement group_id="O3" value="1.5" spread="26.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcB Interval, Aggregate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="41.79"/>
                    <measurement group_id="O2" value="-6.7" spread="24.46"/>
                    <measurement group_id="O3" value="0.4" spread="20.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Augmented</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF Interval, Aggregate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Corrective analysis for these values still being performed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Electrocardiogram (ECG) Heart Rate</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiogram (ECG) Heart Rate</title>
          <population>All treated participants with available measurements</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="8.28"/>
                    <measurement group_id="O2" value="-1.0" spread="9.84"/>
                    <measurement group_id="O3" value="0.0" spread="8.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Diastolic Blood Pressure</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Diastolic Blood Pressure</title>
          <population>All treated participants with available measurements</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="8.67"/>
                    <measurement group_id="O2" value="-0.9" spread="6.10"/>
                    <measurement group_id="O3" value="-1.7" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Heart Rate</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Heart Rate</title>
          <population>All treated participants with available measurements</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="9.40"/>
                    <measurement group_id="O2" value="-2.5" spread="9.02"/>
                    <measurement group_id="O3" value="0.8" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Respiratory Rate</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Respiratory Rate</title>
          <population>All treated participants with available measurements</population>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.88"/>
                    <measurement group_id="O2" value="-0.2" spread="1.46"/>
                    <measurement group_id="O3" value="0.2" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Systolic Blood Pressure</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Systolic Blood Pressure</title>
          <population>All treated participants with available measurements</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="11.05"/>
                    <measurement group_id="O2" value="-0.6" spread="10.95"/>
                    <measurement group_id="O3" value="-1.5" spread="11.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Temperature</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Temperature</title>
          <population>All treated participants with available measurements</population>
          <units>Celsius degree (C)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.307"/>
                    <measurement group_id="O2" value="-0.07" spread="0.364"/>
                    <measurement group_id="O3" value="-0.06" spread="0.323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs - Weight</title>
        <time_frame>From baseline (day of first dose) to 16 weeks after first dose</time_frame>
        <population>All treated participants with available measurements</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matching BMS-986165</description>
          </group>
          <group group_id="O2">
            <title>BMS-986165 6 mg</title>
            <description>BMS-986165 6 mg administered QD for 16 weeks</description>
          </group>
          <group group_id="O3">
            <title>BMS-986165 12 mg</title>
            <description>BMS-986165 12 mg administered QD for 16 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs - Weight</title>
          <population>All treated participants with available measurements</population>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="3.690"/>
                    <measurement group_id="O2" value="0.18" spread="2.646"/>
                    <measurement group_id="O3" value="0.43" spread="2.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose to 16 weeks after first dose (for participants continuing in the subsequent part of the study) or from first dose up to 30 days following the last dose (up to approximately 19 weeks) for participants who discontinued treatment prior to week 16 after first dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matching BMS-986165</description>
        </group>
        <group group_id="E2">
          <title>BMS-986165 6 mg</title>
          <description>BMS-986165 6 mg administered QD for 16 weeks</description>
        </group>
        <group group_id="E3">
          <title>BMS-986165 12 mg</title>
          <description>BMS-986165 12 mg administered QD for 16 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

